HomeCompareATHA vs BTI

ATHA vs BTI: Dividend Comparison 2026

ATHA yields 29.63% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATHA wins by $91.9K in total portfolio value
10 years
ATHA
ATHA
● Live price
29.63%
Share price
$6.75
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$129.6K
Annual income
$16,960.56
Full ATHA calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — ATHA vs BTI

📍 ATHA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATHABTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATHA + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATHA pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATHA
Annual income on $10K today (after 15% tax)
$2,518.52/yr
After 10yr DRIP, annual income (after tax)
$14,416.48/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, ATHA beats the other by $12,047.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATHA + BTI for your $10,000?

ATHA: 50%BTI: 50%
100% BTI50/50100% ATHA
Portfolio after 10yr
$83.6K
Annual income
$9,873.60/yr
Blended yield
11.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

ATHA
Analyst Ratings
5
Hold
Consensus: Hold
Price Target
$13.33
+97.5% upside vs current
Range: $3.00 — $33.00
Altman Z
-18.3
Piotroski
1/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATHA buys
0
BTI buys
0
No recent congressional trades found for ATHA or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATHABTI
Forward yield29.63%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$129.6K$37.7K
Annual income after 10y$16,960.56$2,786.64
Total dividends collected$88.0K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$13.33$40.00

Year-by-year: ATHA vs BTI ($10,000, DRIP)

YearATHA PortfolioATHA Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$13,663$2,962.96$11,299$598.92+$2.4KATHA
2$18,403$3,783.44$12,794$703.91+$5.6KATHA
3$24,454$4,762.59$14,518$829.07+$9.9KATHA
4$32,080$5,914.49$16,513$978.64+$15.6KATHA
5$41,577$7,251.43$18,827$1,157.84+$22.8KATHA
6$53,271$8,783.33$21,518$1,373.12+$31.8KATHA
7$67,517$10,517.46$24,657$1,632.46+$42.9KATHA
8$84,701$12,458.13$28,329$1,945.74+$56.4KATHA
9$105,237$14,606.49$32,637$2,325.33+$72.6KATHA
10$129,564$16,960.56$37,708$2,786.64+$91.9KATHA

ATHA vs BTI: Complete Analysis 2026

ATHAStock

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Full ATHA Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ATHA vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATHA vs SCHDATHA vs JEPIATHA vs OATHA vs KOATHA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.